Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06890598 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Study acronym: SUNRAY-02
StatusRecruiting
PhasePhase 3
Started2025-03-27
View on ClinicalTrials.gov ↗
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Amendment history 4 changes detected by DataLookout

2026-08-08
Trial sites expanded: 366 → 370 locations
2026-07-17
Primary endpoint(s) modified
WasPart A: Disease-Free Survival (DFS) by Investigator Assessment, Part B: Progression-Free Survival (PFS)
NowPart A: Disease-Free Survival (DFS) by Investigator Assessment, Part B: Progression-Free Survival (PFS) by BICR
2026-06-19
Trial sites expanded: 361 → 364 locations
2026-06-04
Trial sites expanded: 354 → 361 locations
Trial Details
NCT Number NCT06890598
Lead Sponsor Eli Lilly and Company
Collaborators: AstraZeneca
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 700 participants
Start Date 2025-03-27
Primary Completion 2029-05 (estimated)
Study Completion 2032-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-24